1
|
Sanabria A, Bradley P, de Bree R, Guntinas-Lichius O, Hamoir M, Kowalski LP, Rodrigo JP, Strojan P, Vander Poorten V, Ferlito A. Deciding whether to do elective neck dissection in patients with salivary gland tumors with no evidence of neck lymph node metastasis. Eur Ann Otorhinolaryngol Head Neck Dis 2025:S1879-7296(25)00023-7. [PMID: 39966080 DOI: 10.1016/j.anorl.2025.02.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2024] [Revised: 01/25/2025] [Accepted: 02/01/2025] [Indexed: 02/20/2025]
Abstract
AIM The treatment of salivary gland cancers with clinically negative neck is controversial, with divergent guidelines about elective neck dissection (END). Even though these guidelines are widely used, they mostly rely on retrospective research that are subject to methodological flaws and selection bias. METHODS A critical narrative review. Problem description, identification of likely clinical scenarios, appraisal of previous recommendations, critical examination of available data, and presentation of clinical decision-making options comprised the article creation. RESULTS One of the most important factors is the rate of occult lymph node metastases, which ranges from 2-30% and varies greatly depending on the kind and grade of tumor. The use of risk classification according to preoperative findings, such as tumor size, grade, and clinical signs such involvement of the facial nerve, offers some guidance. Nevertheless, unanticipated cancers are frequently discovered by intraoperative and postoperative histological results, which makes decision-making even more difficult. Alternatives to END, including elective neck irradiation, have similar effectiveness in reducing regional recurrence in high-risk scenarios. Although END may enhance regional control, it carries risks of surgical complications, such as injury to nerves and functional impairment. No prospective randomized studies have definitively demonstrated the advantage of END regarding survival or recurrence. CONCLUSION END may be appropriate in certain high-risk situations, but its regular use in cN0 salivary gland cancers is still up for debate. A personalized strategy that accounts for tumor-specific and patient-related variables, together with careful use of adjuvant treatments, is advised until substantial prospective data is available.
Collapse
Affiliation(s)
- A Sanabria
- Department of Surgery, Universidad de Antioquia, Hospital Universitario San Vicente Fundación, CEXCA Centro de Excelencia en Enfermedades de Cabeza y Cuello, 1226 Medellin, Colombia.
| | - P Bradley
- Department of Otolaryngology Head and Neck Surgery, Nottingham University Hospitals, Queens Centre Campus, Nottingham, United Kingdom
| | - R de Bree
- Department of Head and Neck Surgical Oncology, University Medical Center Utrecht, Utrecht University, 3584 CX Utrecht, The Netherlands
| | - O Guntinas-Lichius
- Department of Otorhinolaryngology, Head and Neck Surgery, Jena University Hospital, 07747 Jena, Germany
| | - M Hamoir
- Department of Otorhinolaryngology, Head and Neck Surgery, UC Louvain, St Luc University Hospital and King Albert II Cancer Institute, Institut de Recherche Experimentale, 1200 Brussels, Belgium
| | - L P Kowalski
- Department of Otorhinolaryngology Head and Neck Surgery, A.C. Camargo Cancer Center, Faculty of Medicine, University of Sao Paulo, 03828-000 São Paulo, Brazil
| | - J P Rodrigo
- Department of Otolaryngology, Hospital Universitario Central de Asturias and Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Instituto Universitario de Oncología del Principado de Asturias, University of Oviedo, 33011 Oviedo, Spain; CIBERONC, Madrid, Spain
| | - P Strojan
- Department of Radiotherapy, Institute of Oncology, Ljubljana, Slovenia
| | - V Vander Poorten
- Otorhinolaryngology - Head and Neck Surgery, University Hospitals Leuven, Louvain, Belgium; Department of Oncology, Section Head and Neck Oncology, KU Leuven, 3000 Leuven, Belgium
| | - A Ferlito
- Coordinator of the International Head and Neck Scientific Group, 35100 Padua, Italy
| |
Collapse
|
2
|
Vergez S, Chabrillac E, Fakhry N. Salivary gland cancer: Recommendations by formal consensus, for the French Network of Rare Head and Neck Tumors (REFCOR). Eur Ann Otorhinolaryngol Head Neck Dis 2024; 141:3-4. [PMID: 38092570 DOI: 10.1016/j.anorl.2023.11.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2024]
Affiliation(s)
- S Vergez
- Département de chirurgie ORL et cervico-faciale, CHU de Toulouse-Larrey, université Toulouse III Paul-Sabatier, Toulouse, France; Département de chirurgie, institut universitaire du cancer Toulouse - Oncopole, Toulouse, France.
| | - E Chabrillac
- Département de chirurgie, institut universitaire du cancer Toulouse - Oncopole, Toulouse, France
| | - N Fakhry
- Département de chirurgie ORL et cervico-faciale, Aix-Marseille université, hôpital La Conception, AP-HM, Marseille, France
| |
Collapse
|